141303-38-0

Basic information

• Product Name: Oxirane, (2-methoxyphenyl)-, (-)- (9CI)
• Synonyms: Oxirane, (2-methoxyphenyl)-, (-)- (9CI)
• CAS NO: 141303-38-0
• Molecular Formula: C₉H₁₀O₂
• Molecular Weight: 150.1745
• Product Categories: METHOXY
• Mol File: 141303-38-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Oxirane, (2-methoxyphenyl)-, (-)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Oxirane, (2-methoxyphenyl)-, (-)- (9CI)(141303-38-0)
• EPA Substance Registry System: Oxirane, (2-methoxyphenyl)-, (-)- (9CI)(141303-38-0)

Safety Data

• Hazardous Substances Data: 141303-38-0(Hazardous Substances Data)

Upstream product

• 612-15-7 o-methoxystyrene 
• 142363-61-9 2-bromo-1-(2-methoxyphenyl)ethan-1-ol 
• 6814-64-8 methylenedimethyl sulfurane 
• 135-02-4 ortho-anisaldehyde 
• 2181-42-2 trimethylsulphonium iodide 
• 1774-47-6 trimethylsulfoxonium iodide 
• 31949-21-0 bromomethyl 2-methoxyphenyl ketone 
• 64015-63-0 2-chloro-1-(2-methoxyphenyl)ethan-1-ol 
• 333-27-7 methyl trifluoromethanesulfonate 
• 1030268-24-6 trimethylsulphoxonium iodide 
• 67-68-5 dimethyl sulfoxide 
• 2181-44-4 trimethylsulfonium methylsulfate 

Downstream Products

• 142363-63-1 1-(2-methoxyphenyl)-2-(n-propylamino)ethanol 
• 102104-64-3 3-<6-<2-hydroxy-2-(o-methoxyphenyl)ethylamino>hexyl>-1,3-thiazolidine 
• 13513-82-1 1-(2-methoxyphenyl)ethanol 
• 33567-59-8 (2-methoxy-phenyl)-acetaldehyde 
• 1009308-78-4 C₁₉H₂₁NO₂ 
• 1009308-90-0 C₁₅H₁₆O₂S 
• 1434652-62-6 2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethan-1-ol 
• 1434652-66-0 (R)-2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethan-1-ol 
• 1434657-42-7 C₂₉H₃₃N₅O₇S 
• 1434635-54-7 2-(1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol-2-yl)-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine-3(2H)-yl)-2-methylpropanoic acid 
• 1434639-73-2 2-[1-[(2R)-2-hydroxy-2-(2-methoxyphenyl)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxo-1H,2H,3H,4H-thieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid 
• 1434641-93-6 2-[6-bromo-1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-2,4-dioxo-1H,2H,3H,4H-thieno[2,3-d]pyrimidin-3-yl]acetamide 
• 1434642-08-6 2-[5-methyl-1-[(2R)-2-(oxan-4-yloxy)-2-phenylethyl]-6-(1,3-oxazol-2-yl)-2,4-dioxo-1H,2H,3H,4H-thieno[2,3-d]pyrimidin-3-yl]acetamide 
• 1434642-13-3 1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-3-(4H-1,2,4-triazol-3-ylmethyl)-1H,2H,3H,4H-thieno[2,3-d]pyrimidine-2,4-dione 

Relevant articles and documents

SPIRO COMPOUND AND MEDICAL USES THEREOF

The present invention relates to a spiro compound and medical uses thereof. Specifically, the present invention relates to a spiro compound represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the s

Bicyclic derivative-containing inhibitor, preparation method and applications thereof

The invention relates to a bicyclic derivative-containing inhibitor, a preparation method and applications thereof, particularly to a compound represented by a general formula (I), and a preparation method thereof, a pharmaceutical composition containing the compound, and applications of the compound as an Acetyl-CoA Carboxylase (ACC) inhibitor in treatment of diseases or symptoms caused by fattyacid metabolic disorder.

CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

The present invention relates to a cyano-substituted heteroarylpyrimidinone derivative represented by formula (I), a preparation method therefor and a use thereof as a therapeutic agent, in particular a use as an acetyl-CoA carboxylase (ACC) inhibitor, an

Preparation method of thienopyrimidinedione compound

The invention provides a preparation method of a compound shown as a general formula c, wherein the definition of substituent is as defined in the specification. Please see the specification for the formula.

ESTER ACC INHIBITORS AND USES THEREOF

The present invention provides ester compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF

The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.

TRIAZOLE ACC INHIBITORS AND USES THEREOF

The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

Three powerful dinuclear metal-organic catalysts for converting CO2 into organic carbonates

Developing efficient catalysts for converting carbon dioxide (CO2) into varied organic carbonates is an important scientific goal. By using the NH2-functionalized tripodal ligand 2-((bis(2-aminoethyl)amino)methyl)phenol (HL), three dinuclear metal-organic complexes [Zn(L)]2·2ClO4 (1), [Cu(L)]2·2ClO4·2H2O (2) and [Cd(L)]2·2ClO4 (3) have been successfully isolated and structurally characterized using single-crystal X-ray diffraction analyses. Considering the dinuclear metal centers and the NH2-functional groups in the structures, 1-3 were investigated as catalysts for converting CO2 into organic carbonates, and the results show that 1-3 exhibit an outstanding ability for converting CO2 into varied organic carbonates at atmospheric pressure (0.1 MPa). The catalytic system also displays a wide substrate scope and high catalytic activity, and the reaction mechanism has been proposed herein.

PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases

The present invention relates to novel salts of thiazolidinediones and other pharmaceutical agents that are useful for treating and/or preventing metabolic diseases (e.g., diabetes, or neurodegenerative diseases (e.g., Alzheimer's Disease).

PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The present invention relates to PPARy- sparing compounds and pharmaceutical compositions formulated with such compounds that are useful for treating, delaying the onset of, or reducing the symptoms of a neurodegenerative disorder including Huntington's disease, epilepsy, AMS, and MS.